203 related articles for article (PubMed ID: 30570582)
21. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Nast A; Gisondi P; Ormerod AD; Saiag P; Smith C; Spuls PI; Arenberger P; Bachelez H; Barker J; Dauden E; de Jong EM; Feist E; Jacobs A; Jobling R; Kemény L; Maccarone M; Mrowietz U; Papp KA; Paul C; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Yawalkar N
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2277-94. PubMed ID: 26481193
[No Abstract] [Full Text] [Related]
22. Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison.
Wang Y; Wang H; Jiang J; Zhao D; Liu Y
Cell Physiol Biochem; 2016; 39(5):1679-1694. PubMed ID: 27643888
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Lin KM; Cheng TT; Lin JC; Chen CJ
Clin Rheumatol; 2015 Jun; 34(6):1039-46. PubMed ID: 25939523
[TBL] [Abstract][Full Text] [Related]
24. [New ways in the management of rheumatoid arthritis in Hungary].
Gergely P; Poór G
Lege Artis Med; 2007 Oct; 17(10):657-64. PubMed ID: 19227595
[TBL] [Abstract][Full Text] [Related]
25. Clinical consequences of sesquiterpene lactone mix contact allergy in Denmark.
Andersen RM; Skov L; Menné T; Johansen JD
Br J Dermatol; 2015; 172(5):1430-1. PubMed ID: 25639622
[No Abstract] [Full Text] [Related]
26. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Lichtenstein GR; Abreu MT; Cohen R; Tremaine W;
Gastroenterology; 2006 Mar; 130(3):935-9. PubMed ID: 16530531
[No Abstract] [Full Text] [Related]
27. [Uveitic macular edema and the pharmacotherapy].
Liu X; Zhang M
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):151-4. PubMed ID: 25908007
[TBL] [Abstract][Full Text] [Related]
28. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
29. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Lichtenstein GR; Abreu MT; Cohen R; Tremaine W;
Gastroenterology; 2006 Mar; 130(3):940-87. PubMed ID: 16530532
[No Abstract] [Full Text] [Related]
30. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
31. [Crohn's disease--standards of treatment 2004].
Kruis W
Praxis (Bern 1994); 2005 Oct; 94(41):1595-8. PubMed ID: 16245637
[TBL] [Abstract][Full Text] [Related]
32. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
[TBL] [Abstract][Full Text] [Related]
33. Current therapy in sarcoidosis, the role of existing drugs and future medicine.
Vorselaars AD; van Moorsel CH; Deneer VH; Grutters JC
Inflamm Allergy Drug Targets; 2013 Dec; 12(6):369-77. PubMed ID: 24151828
[TBL] [Abstract][Full Text] [Related]
34. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
35. Advances in Pediatric Inflammatory Bowel Disease.
Maxwell EC; Grossman AB
Adolesc Med State Art Rev; 2016; 27(1):57-74. PubMed ID: 27363233
[No Abstract] [Full Text] [Related]
36. Systemic Agents for Severe Atopic Dermatitis in Children.
Notaro ER; Sidbury R
Paediatr Drugs; 2015 Dec; 17(6):449-57. PubMed ID: 26547214
[TBL] [Abstract][Full Text] [Related]
37. [Systemic treatment of cutaneous lupus erythematosus].
Wenzel J; Bieber T; Uerlich M; Tüting T
J Dtsch Dermatol Ges; 2003 Sep; 1(9):694-704. PubMed ID: 16285276
[TBL] [Abstract][Full Text] [Related]
38. The future of inflammatory bowel disease care.
Sandborn WJ
Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
[TBL] [Abstract][Full Text] [Related]
39. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
40. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
